Patent · US Active

Drug combination

US9717732B2 · kind B2 · utility

10Cited by

5References

11Claims

0Family size

Assignee

Verona Pharma PLC · GB

Inventors

Michael J. A. Walker · Vancouver, CA
Mario Cazzola · Napoli, IT
Luigino Calzetta · Roma, IT

Key dates

Filing date	Mar 17, 2014
Grant date	Aug 1, 2017
Priority date	—
Expiry date	Mar 17, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61M2202/064
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a β2-adrenergic receptor agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.